Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Diabetic Retinopathy Treatment – Global Market Outlook (2015-2022)

Thursday, November 17, 2016 4:35
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Get request sample - 
http://www.researchbeam.com/diabetic-retinopathy-treatment-global-outlook-2015-2022-market/request-sample

Global Diabetic Retinopathy Treatment market is expected to reach $10.24 billion by 2022. Rising prevalence of diabetics, increasing management financial support, change in lifestyle and global aging population are the factors driving the market growth. However, Lack of accurate diagnosis, a lack of skilled ophthalmologist coupled with poor infrastructure and extended approval time for drugs are hampering the growth of global diabetic retinopathy market. Increase in awareness of diabetic retinopathy treatment and improvement of patient monitoring are some of the major trends in the market. The two main stages of diabetic retinopathy are non-proliferated and proliferated. Proliferated diabetic retinopathy is the mainly insecure stage and has the risk of detachment into the vitreous leading to severe vision loss.

North America leads the global diabetic retinopathy market due to vast number of aging population. The Asia Pacific diabetic retinopathy market is expected to witness profitable growth over the estimated period due to the occurrence of unmet needs in the developing countries such as China and India. These countries are expected to be the fastest growing diabetic retinopathy markets in Asia-Pacific region.

Some of the key players in the market include Regeneron Pharmaceuticals Inc., ThromboGenics, Genentech, Bayer Healthcare, Alimera Sciences, Actavis PLC, BCN Peptides, Novartis AG, Ampio Pharmaceuticals, Kowa Group, Sirnaomics Incorporation, Abbott Laboratories Ltd, Glycadia Pharmaceuticals, Alcon Laboratories Inc. and Parexel International Corp.

Type of Treatments Covered:
• Intraocular Steroid Injection
• Vitrectomy
• Anti-Vascular Endothelial Growth Factor (VEGF) drug
• Laser Surgery

Disease Type Covered:
• Proliferative Diabetic Retinopathy (PDR)
• Non-Proliferative Diabetic Retinopathy (NPDR)
o Moderate
o Mild
o Severe

End Users Covered:
• Ophthalmic Clinics
• Ambulatory Surgical Centers
• Hospitals
• Other End Users

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o France
o Italy
o UK 
o Spain 
o Rest of Europe 
• Asia Pacific
o Japan 
o China 
o India 
o Australia 
o New Zealand 
o Rest of Asia Pacific 
• Rest of the World
o Middle East
o Brazil
o Argentina
o South Africa
o Egypt

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.